Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000459017 | SCV000544372 | benign | Tuberous sclerosis 2 | 2025-01-22 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000522580 | SCV000620377 | uncertain significance | not provided | 2022-07-29 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV000561438 | SCV000675698 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-02-08 | criteria provided, single submitter | clinical testing | The p.L1398V variant (also known as c.4192C>G), located in coding exon 33 of the TSC2 gene, results from a C to G substitution at nucleotide position 4192. The leucine at codon 1398 is replaced by valine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Genome- |
RCV000459017 | SCV002040810 | uncertain significance | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing |